Cumencor Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cumencor Pharmaceuticals Inc.
The JV with Shanghai Zhangjiang Biomedical Industry Venture Capital will fund the development and commercialization of MicuRx’s novel antibiotic MRX-I for the Chinese market.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.